The Experts below are selected from a list of 699 Experts worldwide ranked by ideXlab platform
Rachida Lebtahi - One of the best experts on this subject based on the ideXlab platform.
-
Detection of Neuroendocrine Tumors: 99mTc-P829 Scintigraphy Compared with 111In-Pentetreotide
2015Co-Authors: Rachida Lebtahi, Phd Joseph, Le Cloirec, Md Claire Houzard, Md Doumit DaouAbstract:The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-Pentetreotide. Methods: Forty-three patients (32 men, 11 women; age range, 24–78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 pa-tients with carcinoid tumors, and 16 patients with other types of functioning (n 6) or nonfunctioning (n 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 g soma-tostatin analog labeled with 148 17 MBq 111In, and SPECT was performed 24 h after injection. Similar 99mTc-P829 planar images were obtained at 1, 4–6, and 24 h after injection of 50 g peptide labeled with 991.6 187.59 MBq 99mTc. Abdominal SPECT was performed 4–6 h after injection. Results: 111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P 0.005). In the liver, 129 sites (in 24 patients) were detected by 111In-Pentetreotide scintigraphy and 34 sites (in 10 patients) were detected by 99mTc-P829 scintigraphy. Con-clusion: In patients with endocrine tumors, the detection rate of 99mTc-P829 scintigraphy was lower than that of 111In-pentet-reotide scintigraphy, which appeared to be more sensitive, es-pecially for liver metastases. Key Words: somatostatin receptor scintigraphy; 99mTc-P829 scintigraphy; endocrine tumor
-
enets consensus guidelines for the standards of care in neuroendocrine tumors somatostatin receptor imaging with iiiin Pentetreotide
Neuroendocrinology, 2009Co-Authors: D J Kwekkeboom, E. P. Krenning, Rachida Lebtahi, Klemens Scheidhauer, Val Lewington, A Grossman, Pavel Vitek, Anders Sundin, Ursula Plockinger, Goran AkerstromAbstract:ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : Somatostatin Receptor Imaging with In-111-Pentetreotide
-
detection of neuroendocrine tumors 99mtc p829 scintigraphy compared with 111in Pentetreotide scintigraphy
The Journal of Nuclear Medicine, 2002Co-Authors: Rachida Lebtahi, Joseph Le Cloirec, Claire Houzard, Doumit Daou, Iradj Sobhani, Genevieve Sassolas, M Mignon, P Bourguet, Dominique Le GuludecAbstract:The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-Pentetreotide. Methods: Forty-three patients (32 men, 11 women; age range, 24–78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 μg somatostatin analog labeled with 148 ± 17 MBq 111In, and SPECT was performed 24 h after injection. Similar 99mTc-P829 planar images were obtained at 1, 4–6, and 24 h after injection of 50 μg peptide labeled with 991.6 ± 187.59 MBq 99mTc. Abdominal SPECT was performed 4–6 h after injection. Results:111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P
-
111in Pentetreotide scintigraphy in patients with langerhans cell histiocytosis
The Journal of Nuclear Medicine, 2000Co-Authors: Pierre Weinmann, Dominique Le Guludec, Bruno Crestani, Abdelatif Tazi, Thierry Genereau, Herve Mal, M Aubier, Dominique Valeyre, J L Moretti, Rachida LebtahiAbstract:Langerhans’ cell histiocytosis is a granulomatous disease that may involve multiple organs and the prognosis of which is highly variable. Because the prognosis depends particularly on the number of tissues involved, the accurate identification of the organs involved by granulomatous lesions is of critical importance. We hypothesized that 111 In-Pentetreotide scintigraphy would be useful for evaluation of patients with Langerhans’ cells histiocytosis. Methods: Thirteen patients (38.3 6 10.4 y) with Langerhans’ cell histiocytosis (8 patients with unifocal lung disease, 5 with multifocal disease) received intravenous 111 InPentetreotide (111‐222 MBq), and planar images were obtained at 24 h after injection. Pulmonary uptake was quantified using a lung-to-background ratio (L/B) and compared with a population of 10 normal scintigrams. For the other sites, uptake of radioactivity in disease-related areas was visually assessed. Results: Ten of 12 patients with lung involvement had increased lung uptake (L/B, 2.23 6 0.49 versus 1.34 6 0.07; P , 0.001). In the patients with multifocal disease, increased 111 In-Pentetreotide uptake was found in disease-related areas such as the salivary glands, the skin, the soft tissues, and the bones. However, somatostatin receptor imaging was insensitive for detecting central nervous system and liver involvement and most skin lesions. Conclusion: 111In-Pentetreotide imaging may be useful in Langerhans’ cell histiocytosis. Further study will indicate whether 111In-pente
Stanislas Pauwels - One of the best experts on this subject based on the ideXlab platform.
-
pre therapeutic dosimetry and biodistribution of 86y dota phe1 tyr3 octreotide versus 111in Pentetreotide in patients with advanced neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging, 2004Co-Authors: Andreas Helisch, Stanislas Pauwels, Gregor J Forster, Helmut Reber, Hansgeorg Buchholz, R Arnold, Burkhard Goke, Matthias M Weber, B Wiedenmann, Ulrike HausAbstract:PURPOSE: For the internal radiotherapy of neuroendocrine tumours, the somatostatin analogue DOTATOC labelled with 90Y is frequently used [90Y-DOTA-Phe1-Tyr3)-octreotide (SMT487-OctreoTher)]. Radiation exposure to the kidneys is critical in this therapy as it may result in renal failure. The aim of this study was to compare cumulative organ and tumour doses based upon dosimetric data acquired with the chemically identical 86Y-DOTA-Phe1-Tyr3-octreotide (considered as the gold standard) and the commercially available 111In-Pentetreotide. METHODS: The cumulative organ and tumour doses for the therapeutic administration of 13.32 GBq 90Y-DOTA-Phe1-Tyr3-octreotide (three cycles, each of 4.44 GBq) were estimated based on the MIRD concept (MIRDOSE 3.1 and IMEDOSE). Patients with a cumulative kidney dose exceeding 27 Gy had to be excluded from subsequent therapy with 90Y-DOTA-Phe1-Tyr3-octreotide, in accordance with the directives of the German radiation protection authorities. RESULTS: The range of doses (mGy/MBq 90Y-DOTA-Phe1-Tyr3-octreotide) for kidneys, spleen, liver and tumour masses was 0.6-2.8, 1.5-4.2, 0.3-1.3 and 2.1-29.5 (86Y-DOTA-Phe1-Tyr3-octreotide), respectively, versus 1.3-3.0, 1.8-4.4, 0.2-0.8 and 1.4-19.7 (111In-Pentetreotide), with wide inter-subject variability. Despite renal protection with amino acid infusions, estimated cumulative kidney doses in two patients exceeded 27 Gy. CONCLUSION: Compared with 86Y-DOTA-Phe1-Tyr3-octreotide, dosimetry with 111In-Pentetreotide overestimated doses to kidneys and spleen, whereas the radiation dose to the tumour-free liver was underestimated. However, both dosimetric approaches detected the two patients with an exceptionally high radiation burden to the kidneys that carried a potential risk of renal failure following radionuclide therapy.
-
uptake of in 111 Pentetreotide by pleural plaques
Clinical Nuclear Medicine, 1998Co-Authors: Max Lonneux, Francois Jamar, N Leners, Thierry Pieters, Stanislas PauwelsAbstract:Somatostatin receptor imaging with In-111 Pentetreotide has been validated for the diagnosis and staging of chest tumors with neuroendocrine differentiation such as bronchial carcinoid and small cell lung cancer. In-111 Pentetreotide uptake is not specific for neuroendocrine tumors because somatostatin receptors are also expressed by white blood cells, leading to the in vivo visualization sites of infection sites or active inflammation. Pleural plaques may be due to asbestos exposure or tuberculosis. Presented here are three cases of In-111 Pentetreotide uptake in pleural plaques. This uptake by benign lesions may be misleading in the diagnostic work-up of patients with lung tumors.
-
indium 111 Pentetreotide uptake in endocrine tumors and lymphoma
The Journal of Nuclear Medicine, 1996Co-Authors: N Leners, Francois Jamar, Rene Fiasse, Augustin Ferrant, Stanislas PauwelsAbstract:The biodistribution of 111In-Pentetreotide was assessed in patients with gastroenteropancreatic (GEP) neuroendocrine tumors or lymphoma and in control patients and analyzed as a function of scanning time, presence or absence of tumor uptake, tumor type and previous octreotide treatment. METHODS: Patients underwent imaging 4 and 24 hr after injection of approximately 200 MBq 111In-Pentetreotide. The frequency of organ visualization was assessed on planar views. Total organ and tumor uptake (% injected dose [ID]) was determined using the geometric mean method and regional tissue uptake (% ID/100 ml) by semiquantitative SPECT. RESULTS: Liver, spleen, kidneys and urinary bladder were visualized in all patients. Thyroid, bowel and pituitary were more often visualized at 24 hr than at 4 hr. Activity in the gallbladder, breast, ureters and ascites was only occasionally observed. Total liver, spleen and thyroid uptake was stable over time, whereas kidney activity decreased slightly. At 24 hr, regional uptake was threefold lower in the liver than in the spleen or kidneys and was similar in the three groups. In patients with long-term octreotide therapy, a positive correlation was found between the duration of octreotide therapy and liver or spleen uptake. Total and regional tumor uptake showed high intraindividual and interindividual variations. Total tumor activity was stable over 24 hr in patients with GEP and decreased in those with lymphoma. The mean regional tumor uptake was 10-fold lower in patients with lymphoma than in those with GEP. Cold octreotide injected 24 hr after tracer administration did not result in any displacement of organ and tumor activity. CONCLUSION: Organ uptake seems not to be influenced by the presence of 111In-Pentetreotide-positive lesions or by tumor type. Tumor uptake is highly variable among patients and clearly lower in patients with lymphoma than in those with GEP. The widespread of uptake values in tumors indicates that radiotherapy using radiolabeled somatostatin analogs may not be applicable to all patients with 111In-Pentetreotide-positive tumors.
-
somatostatin receptor imaging with indium 111 Pentetreotide in gastroenteropancreatic neuroendocrine tumors safety efficacy and impact on patient management
The Journal of Nuclear Medicine, 1995Co-Authors: Francois Jamar, Rene Fiasse, N Leners, Stanislas PauwelsAbstract:Indium-111-Pentetreotide, a radiolabeled somatostatin analog, has been proposed for imaging tumors bearing somatostatin receptors. This study evaluates the safety, efficacy and impact on patient management of this scintigraphic agent in patients with gastroenteropancreatic (GEP) neuroendocrine tumors. METHODS: We studied 47 consecutive patients with a proven or clinically suspected GEP neuroendocrine tumor who were imaged 4 and 24 hr after injection of 111In-Pentetreotide. The patients were monitored for adverse reactions and changes in vital signs or clinical chemistry over 24 hr. The scintigraphic findings were compared with results from conventional imaging methods. The patients were followed over a minimal 6-mo period during which further localization procedures were performed to confirm or refute the additional tumor sites found at scintigraphy. RESULTS: No adverse reactions or clinically relevant changes in clinical chemistry were noted after injection of the radiopharmaceutical. The final diagnosis of a GEP neuroendocrine tumor was retained in 38 patients. Somatostatin receptor-positive lesions were found in 33 of these patients, whereas conventional methods were positive in 31 patients. Of the 54 sites seen by conventional procedures, 50 sites were also detected scintigraphically. CONCLUSION: Indium-111-Pentetreotide is a safe, sensitive imaging agent in the detection of GEP neuroendocrine tumor sites. Indium-111-Pentetreotide also provides information on the somatostatin receptor status of the tumor and may therefore aid in therapeutic decisions.
Keon Wook Kang - One of the best experts on this subject based on the ideXlab platform.
-
comparison of diagnostic sensitivity and quantitative indices between 68 ga dotatoc pet ct and 111 in Pentetreotide spect ct in neuroendocrine tumors a preliminary report
Nuclear Medicine and Molecular Imaging, 2015Co-Authors: Inki Lee, Jin Chul Paeng, Soojin Lee, Chan Soo Shin, Jinyoung Jang, Gi Jeong Cheon, Dong Soo Lee, Junekey Chung, Keon Wook KangAbstract:In-Pentetreotide has been used for neuroendocrine tumors expressing somatostatin receptors. Recently, 68Ga-DOTATOC PET has been used with the advantage of high image quality. In this study, we compared quantitative indices between 111In-Pentetreotide SPECT/CT and 68Ga-DOTATOC PET/CT. Thirteen patients diagnosed with neuroendocrine tumors were prospectively recruited. Patients underwent 111In-Pentetreotide scans with SPECT/CT and 68Ga-DOTATOC PET/CT before treatment. The number and location of lesions were analyzed on both imaging techniques to compare lesion detectability. Additionally, the maximal uptake count of each lesion and mean uptake count of the lungs were measured on both imagings, and target-to-normal lung ratios (TNR) were calculated as quantitative indices. Among 13 patients, 10 exhibited lesions with increased uptake on 111In-Pentetreotide SPECT/CT and/or 68Ga-DOTATOC PET/CT. Scans with SPECT/CT detected 19 lesions, all of which were also detected on PET/CT. Moreover, 16 additional lesions were detected on PET/CT (6 in the liver, 9 in the pancreas and 1 in the spleen). PET/CT exhibited a significantly higher sensitivity than SPECT/CT (100 % vs. 54 %, P < 0.001). TNR was significantly higher on PET/CT than on SPECT/CT (99.9 ± 84.3 vs. 71.1 ± 114.9, P < 0.001) in spite of a significant correlation (r = 0.692, P = 0.01). Ga-DOTATOC PET/CT has a higher diagnostic sensitivity than 111In-Pentetreotide scans with SPECT/CT. The TNR on PET/CT is higher than that of SPECT/CT, which also suggests the higher sensitivity of PET/CT. 111In-Pentetreotide SPECT/CT should be used carefully if it is used instead of 68Ga-DOTATOC PET/CT.
-
higher sensitivity of 68ga dotatoc pet ct compared with 111in Pentetreotide scan with spect ct in neuroendocrine tumors
The Journal of Nuclear Medicine, 2015Co-Authors: Inki Lee, Jin Chul Paeng, Gi Jeong Cheon, Dong Soo Lee, Junekey Chung, Min Young Yoo, Keon Wook KangAbstract:268 Objectives 111In-Pentetreotide has been used for neuroendocrine tumors expressing somatostatin receptors. Recently, 68Ga-DOTATOC PET is also used with an advantage of high image quality. In this study, we compared quantitative indices between 111In-Pentetreotide SPECT/CT and 68Ga-DOTATOC PET/CT. Methods Thirteen patients diagnosed with neuroendocrine tumors were prospectively recruited. Patients underwent 111In-Pentetreotide scan with SPECT/CT and 68Ga-DOTATOC PET/CT before treatment. Number and location of lesions were analyzed in both imaging. Maximal uptake counts were measured in each lesion and the lungs as the background tissue. Lesion-to-background ratio (LTB) was calculated in SPECT/CT and PET/CT to be compared with each other. Results Among 13 patients, 10 patients exhibited lesions with increased uptake on scan with SPECT/CT and/or PET/CT. Scan with SPECT/CT detected 19 lesions, all of which were also detected on PET/CT. Moreover, 19 additional lesions were detected on PET/CT (7 in the liver, 10 in the pancreas, 1 in the spleen, and 1 in the spine). LTB was significantly higher on PET/CT than on SPECT/CT (52.7 ± 7.6 vs. 30.0 ± 7.5, P Conclusions 68Ga-DOTATOC PET/CT has a higher diagnostic sensitivity than 111In-Pentetreotide scan with SPECT/CT. Additionally, LBR on PET/CT is higher than that of SPECT/CT, which also suggests the higher sensitivity of PET/CT and needs for quantitative assessment using PET/CT.
Dominique Le Guludec - One of the best experts on this subject based on the ideXlab platform.
-
detection of neuroendocrine tumors 99mtc p829 scintigraphy compared with 111in Pentetreotide scintigraphy
The Journal of Nuclear Medicine, 2002Co-Authors: Rachida Lebtahi, Joseph Le Cloirec, Claire Houzard, Doumit Daou, Iradj Sobhani, Genevieve Sassolas, M Mignon, P Bourguet, Dominique Le GuludecAbstract:The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-Pentetreotide. Methods: Forty-three patients (32 men, 11 women; age range, 24–78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 μg somatostatin analog labeled with 148 ± 17 MBq 111In, and SPECT was performed 24 h after injection. Similar 99mTc-P829 planar images were obtained at 1, 4–6, and 24 h after injection of 50 μg peptide labeled with 991.6 ± 187.59 MBq 99mTc. Abdominal SPECT was performed 4–6 h after injection. Results:111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P
-
111in Pentetreotide scintigraphy in patients with langerhans cell histiocytosis
The Journal of Nuclear Medicine, 2000Co-Authors: Pierre Weinmann, Dominique Le Guludec, Bruno Crestani, Abdelatif Tazi, Thierry Genereau, Herve Mal, M Aubier, Dominique Valeyre, J L Moretti, Rachida LebtahiAbstract:Langerhans’ cell histiocytosis is a granulomatous disease that may involve multiple organs and the prognosis of which is highly variable. Because the prognosis depends particularly on the number of tissues involved, the accurate identification of the organs involved by granulomatous lesions is of critical importance. We hypothesized that 111 In-Pentetreotide scintigraphy would be useful for evaluation of patients with Langerhans’ cells histiocytosis. Methods: Thirteen patients (38.3 6 10.4 y) with Langerhans’ cell histiocytosis (8 patients with unifocal lung disease, 5 with multifocal disease) received intravenous 111 InPentetreotide (111‐222 MBq), and planar images were obtained at 24 h after injection. Pulmonary uptake was quantified using a lung-to-background ratio (L/B) and compared with a population of 10 normal scintigrams. For the other sites, uptake of radioactivity in disease-related areas was visually assessed. Results: Ten of 12 patients with lung involvement had increased lung uptake (L/B, 2.23 6 0.49 versus 1.34 6 0.07; P , 0.001). In the patients with multifocal disease, increased 111 In-Pentetreotide uptake was found in disease-related areas such as the salivary glands, the skin, the soft tissues, and the bones. However, somatostatin receptor imaging was insensitive for detecting central nervous system and liver involvement and most skin lesions. Conclusion: 111In-Pentetreotide imaging may be useful in Langerhans’ cell histiocytosis. Further study will indicate whether 111In-pente
Emilio Bombardieri - One of the best experts on this subject based on the ideXlab platform.
-
1111IN-Pentetreotide SCINTIGRAPHY PROCEDURE GUIDELINES FOR TUMOUR IMAGING
2015Co-Authors: Emilio Bombardieri, Richard P Baum, Cumali Aktolun, Jeanfrancois Chatal, Lorenzo Maffioli, Roy Moncayo, Luc Mortelmans, Angelica Bishof-delaloye, Sven NAbstract:The aim of this document is to provide general information about somatostatin receptor scintigraphy with 111In-Pentetreotide, a [111In-DTPA-D-Phe-] conjugate of octreotide that binds to somatostatin receptors. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedure
-
111in Pentetreotide scintigraphy procedure guidelines for tumour imaging
European Journal of Nuclear Medicine and Molecular Imaging, 2003Co-Authors: Emilio Bombardieri, Richard P Baum, Cumali Aktolun, Angelika Bishofdelaloye, J R Buscombe, Jeanfrancois Chatal, Lorenzo Maffioli, Roy Moncayo, Luc Mortelmans, Sven N ReskeAbstract:This document provides general information about somatostatin receptor scintigraphy with 111In-Pentetreotide. This guideline should not be regarded as the only approach to visualise tumours expressing somatostatin receptors or as exclusive of other nuclear medicine procedures useful to obtain comparable results. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of 111In-Pentetreotide scintigraphy.
-
breast cancer staging using technetium 99m sestamibi and indium 111 Pentetreotide single photon emission tomography
European Journal of Nuclear Medicine and Molecular Imaging, 1997Co-Authors: Arturo Chiti, Lorenzo Maffioli, Roberto Agresti, Gorana Tomasic, Giordano Savelli, Flavio Crippa, Silvana Pilotti, M Greco, Emilio BombardieriAbstract:We evaluated the clinical usefulness of single-photon emission tomography (SPET) with technetium-99m sestamibi and indium-111 Pentetreotide in breast cancer staging. Fifteen patients with clinical and/or mammographic findings suggesting T1-2N0-1 breast cancer were studied. SPET images were acquired 20 min after99mTc-sestamibi injection and 4 and 24 h after111In-Pentetreotide injection. Patients underwent surgery the day after the later111In-Pentetreotide acquisition. Pathological examination showed 16 tumours in the 15 patients, with one bilateral carcinoma. The mean tumour diameter was 18.7 mm. Metastatic axillary involvement was found in 6/16 tumours, with a mean of five metastatic nodes per axilla. Both tracers correctly identified 15/16 primary tumours and five of the six cases of metastatic axillary node involvement. No difference between the tracers was observed in breast cancer staging.99mTc-sestamibi seems to be the better tracer in terms of physical characteristics, execution time and cost-effectiveness. Our data suggest the future possibility of using nuclear medicine imaging to avoid axillary dissection in patients with T1 breast cancer.